A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.
about
Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinomaPrime-boost approaches to tuberculosis vaccine developmentMatrix and backstage: cellular substrates for viral vaccinesCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxAnnulling a dangerous liaison: vaccination strategies against AIDS and tuberculosisModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesAvian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetA replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in miceMVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesModified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.Several hemagglutinins of same serotype for induction of broad immunity against influenza A virus antigenic drift variants: WO2008048984.Viral vector-based influenza vaccines.Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceTargets for the induction of protective immunity against influenza a viruses.The development of an AIDS mucosal vaccine.Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccinesExperimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesReplication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesVaccine technology: looking to the future.Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.Mucosal immunity and tolerance: relevance to vaccine development.Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVProtective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicityRecombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.Virus-vectored influenza virus vaccines.Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins
P2860
Q24610485-9DCF9807-D741-4B10-B6BF-0CD56D35855AQ27024526-5EA51B00-1E76-49B3-8BAD-271AAB46A049Q27025941-A90D7050-C548-4829-8FD3-AB8F8EE88FE5Q27346933-B483FB56-F896-41CA-971E-59D3528293B9Q28243702-CB334193-9295-49A0-82D0-0DF01901A6B6Q30209342-BF16A2FD-B22A-4512-8D2F-8D604D13C9D6Q30227194-F058E695-ACBA-4B15-9FEF-F237ECAE180BQ30357094-E54BFD26-68EC-480F-9024-7585FE1BCE66Q30358935-14D6A4CC-F18D-43EB-A8D7-5CD2DF27428EQ30366666-2023172C-2B2C-4CF9-8120-D71B50F148D8Q30375380-AC2547FA-4170-4C06-83A5-631265CE41BCQ30375489-1E06F581-6F48-457A-9853-AF32E060185BQ30375979-90CB9D0D-FE25-4ED2-AD1C-53D71D640FBEQ30382097-48F4CC98-C68D-4794-8C05-212530850B5EQ30382567-8F960BA4-B8AE-4251-984D-39C75E448012Q30385956-0FFAAEA0-CFDD-446E-8681-EFE6DD2E36F3Q30390938-5E994B5C-82AA-4764-9C82-C2AE2B38BB7BQ30392456-E5241CDF-A6C1-46EC-B256-30CB8AE325FAQ30408100-0999A0E6-BCA6-4862-A7FD-212986B102AFQ30408103-AA20BD2F-4F54-4975-A633-4CF8437E8FDDQ30408295-B7C439D5-B10F-4DB2-B72B-0C56EFBE5D2BQ30427591-DE78F2DE-7872-429A-BBF8-FBB9CF94BFFEQ33187731-A6728C15-A6D8-4BA0-9E85-4889A8E0925AQ33320536-DD0C53AF-0D84-4813-9C19-2A2B4496F938Q33440600-DD3C7A28-6512-47CC-9F7A-F04B476D6D85Q33603392-0E925224-4472-4B9D-8C14-002A67EC23C1Q33635050-3489BAF1-EE89-4AAB-AD81-D1525477D1B8Q33776144-13941E34-9DD2-4D1D-B97C-0316B3CE5489Q33776155-3D39A3E8-D057-41A7-82E8-425064501538Q33776172-8176634D-F512-4E6B-BC1C-E99BF41D78D8Q33784928-605166D6-BECF-4F43-ABD4-179C49062495Q33800033-F2D70D29-555A-4CDB-B606-E5CA2ABA9FADQ33803714-6DDA8895-1EEB-4888-8D4C-C1C5B13A9E74Q33834391-AC7A415C-5C22-41D6-A94C-61A74CE451FBQ33834543-2D2E1510-0B30-42B7-9AB5-8A536179C40FQ33938820-614D3B47-B3FB-4E61-AA13-7FB83DFE66D9Q33945612-1E15392A-F9E7-461D-8DF1-AA249571BB2BQ34017475-80AB0CE4-8244-47B7-9402-9D6CD1AA0A14Q34102268-EEE0C11C-FC78-4407-A783-86EEC42FD3ACQ34106038-82561BBA-5090-42D9-B340-0242B2849078
P2860
A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
A recombinant vector derived f ...... ty in mice to influenza virus.
@en
A recombinant vector derived f ...... ty in mice to influenza virus.
@nl
type
label
A recombinant vector derived f ...... ty in mice to influenza virus.
@en
A recombinant vector derived f ...... ty in mice to influenza virus.
@nl
prefLabel
A recombinant vector derived f ...... ty in mice to influenza virus.
@en
A recombinant vector derived f ...... ty in mice to influenza virus.
@nl
P2093
P1433
P1476
A recombinant vector derived f ...... ty in mice to influenza virus.
@en
P2093
P304
P356
10.1016/0264-410X(94)90341-7
P407
P50
P577
1994-08-01T00:00:00Z